Abstracts tagged "Biomarkers"

Abstract Number: 2180 • ACR Convergence 2023
Salivary and Plasma Mitochondrial Double-strand RNAs as a Diagnostic Biomarker for Sjӧgren Syndrome
SE RIM CHOI¹, Jee-in Lee², Yong Seok Choi³, You-Jung Ha³, Eun Ha Kang³ and Yun Jong Lee⁴, ¹Seoul National University Bundang Hospital, Seoul, South Korea, ²Seoul National University of Bundang Hospital, Seongnam, South Korea, ³Seoul National University Bundang Hospital, Seongnam, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea
Background/Purpose: Since mitochondrial double-stranded RNAs (mt-dsRNAs), an endogenous activator of interferon signaling, are elevated in primary Sjӧgren's syndrome (pSS), we evaluated their association with the…
Abstract Number: 2354 • ACR Convergence 2023
Is Midkine a Novel Biomarker for Acro-osteolysis in Systemic Sclerosis?
Ganiat Adeogun¹, Venkateswara Gogulamudi², Meridith Balbach¹, Anthony Donato² and Tracy Frech¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT
Background/Purpose: Acro-osteolysis is a hand complication in systemic sclerosis (SSc) characterized by the destruction of distal digital bone possibly related to repetitive ischemia-reperfusion injury. Diagnosis…
Abstract Number: 2495 • ACR Convergence 2023
Unbiased Proteomic Approach to Identify Novel Biomarkers of Disease Activity in ANCA- Associated Vasculitis
Natalie Atallah¹, Vahe Panossian², Xiaoqing Fu¹, Claire Cook¹ and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²American University of Beirut, Beirut, Lebanon, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: Identifying novel biomarkers of disease activity could improve outcomes by facilitating personalized approaches to treatment decisions in ANCA-associated vasculitis. Biomarkers of disease activity used…
Abstract Number: 0023 • ACR Convergence 2023
Proteomic Analysis of Plasma-derived Extracellular Vesicles Renders Glutathione Peroxidase 3 a Biomarker for Dermatomyositis
Avital Baniel¹, Mariko Ogawa-Momohara², Muhammad Bashir³, Rachita Pandya¹, Julianne Kleitsch¹, Felix Chin⁴, Ming-Lin Liu¹ and Victoria P. Werth⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵University of Pennsylvania, Wynnewood, PA
Background/Purpose: Extracellular vesicles (EVs) have been implicated in autoimmune disease pathogenesis. Plasma-derived DNA containing EVs have been shown to induce STING-mediated proinflammatory responses in dermatomyositis…
Abstract Number: 0373 • ACR Convergence 2023
Potential Tear-Based Uveitis Biomarkers in Children with JIA: A Pilot Study
Ilaria Maccora¹, Mekibib Altaye², Tiffany Nguyen³, Kenneth Greis⁴, Wendy Haffey⁴, Theresa Hennard⁵, Alyssa Sproles², Sherry Thornton², Virginia Miraldi Utz⁵ and Sheila Angeles-Han², ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Eye Institute, Cincinnati, OH, ⁴University of Cincinnati, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Children with oligoarticular JIA are at increased risk of developing uveitis. JIA category, ANA positivity, ≤4 years JIA duration, and < 6 years old…
Abstract Number: 0576 • ACR Convergence 2023
Enhancing Systemic Lupus Erythematosus Diagnosis: Comparative Performance Characteristics of TC4d and Anti-T-Cell Antibodies with Conventional Biomarkers
Andrew Concoff¹, Vasileios Kyttaris², Vaneet Sandhu³, Tyler O'Malley⁴, Giorgio Casaburi⁴, Sudha Kumar⁴, Chau Ching Liu⁵, Susan Manzi⁶ and Joeseph Ahearn⁵, ¹Exagen, Los Angeles, CA, ²BIDMC, Boston, MA, ³Loma Linda University, Loma Linda, CA, ⁴Exagen, Vista, CA, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, systemic autoimmune disease, affecting multiple organ systems with varying severity among patients. SLE presents a diagnostic challenge…
Abstract Number: 0789 • ACR Convergence 2023
Telomere Length of Peripheral Blood Cells Predicts More Severe Pulmonary Disease and Worse Survival in Systemic Sclerosis
Monica Yang¹, Shuo Liu², Seoyeon Lee³, Sarah French¹, Paul Wolters¹ and Francesco Boin⁴, ¹University of California San Francisco, San Francisco, CA, ²Fourth Hospital of China Medical University, Shenyang, China, ³Yale University School of Medicine, New Haven, CT, ⁴Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Peripheral blood leukocyte telomere length (PBL-TL) has been associated with disease and organ specific morbidity and mortality in conditions associated with pulmonary fibrosis including…
Abstract Number: 0963 • ACR Convergence 2023
Anti-Topoisomerase Antibody in dcSSc: Unravelling Its Intracellular Effects in Systemic Sclerosis
Maithri Aspari¹, Josephine Geertsen Keller-Socin¹, Stinne Greisen², Esben Naeser³, Klaus Soendergaard⁴, Birgitta R Knudsen⁵, Voon Ong⁶, Christopher Denton⁷, David Abraham⁷ and Bent Deleuran¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University/Aarhus University Hospital, Aarhus, Denmark, ³Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Aarhus University Hospital, Aarhus, Denmark, ⁵Institute for molecular Biology, Aarhus University, Aarhus, Denmark, ⁶UCL Medical School Royal Free Campus, London, United Kingdom, ⁷University College London, London, United Kingdom
Background/Purpose: The presence of autoantibodies, especially directed towards topoisomerase I (ATA), in diffuse cutaneous Systemic Sclerosis (dcSSc) is known to be associated with severe clinical…
Abstract Number: 1302 • ACR Convergence 2023
Biomarkers of Cardiovascular Risk in Patients with Rheumatoid Arthritis: Results from the TARGET Trial Biomarker Study
Daniel Solomon¹, Olga Demler², Pamela Rist², Leah Santacroce¹, Jon Giles³, Katherine Liao¹ and Joan Bathon³, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Columbia University, New York, NY
Background/Purpose: Cardiovascular (CV) disease remains an important source of morbidity and the most common cause of mortality in patients with rheumatoid arthritis (RA). It has…
Abstract Number: 1633 • ACR Convergence 2023
Dose Dependent Modulation of a B Cell Protein Signature by Ianalumab in Patients with Sjögren’s Disease
Stephanie Finzel¹, Andrea Grioni², Benjamin A Fisher³, Athena S Papas⁴, Alexandre Avrameas², Danny Tuckwell², Jonas Zierer², Celine Rauld², Valeria De Luca², Enrico Ferrero², Andre Nogueira da Costa², Rainer Hillenbrand², Isabelle Isnardi² and Wolfgang Hueber², ¹Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³University of Birmingham, Birmingham, United Kingdom, ⁴Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA
Background/Purpose: Ianalumab (VAY736) is an afuscosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…
Abstract Number: 1765 • ACR Convergence 2023
Persistent Cigarette Smoking Is Associated with Rheumatoid Arthritis Onset and Neutrophil Activation in a Prospective Study of At-risk First-Degree Relatives
Jeba Maisha, Xiaobo Meng, Hani El-Gabalawy and Liam O'Neil, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Cigarette smoking (CS) is a major environmental risk factor for the development of Rheumatoid Arthritis (RA), and is associated with the development of RA…
Abstract Number: 2195 • ACR Convergence 2023
Regional Differences in Clinical Phenotype of Axial Spondyloarthritis. Results from the International Map of Axial Spondyloarthritis (IMAS)
Denis Poddubnyy¹, Fernando Sommerfleck², Victoria Navarro-Compán³, Christine Bundy⁴, Souzi Makri⁵, Shashank Murlidhar Akerkar⁶, Lillann Wermskog⁷, Elie Karam⁸, Jose Correa Fernandez⁹, Asif Siddiqui¹⁰ and Marco Garrido-Cumbrera¹¹, ¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Sanatorio Julio Mendez, Buenos Aires, Argentina, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Cardiff University, Cardiff, United Kingdom, ⁵Cyprus League for People with Rheumatism (CYLPER), Nicosia, Cyprus, ⁶Mumbai Arthritis Clinic, Mumbai, India, ⁷Spondyloarthritis Association of Norwary (SPAFO);Axial Spondyloarthritis International Federation (ASIF), Oslo, Norway, ⁸Canadian Spondylitis Association (CSA), Toronto, ON, Canada, ⁹Universidad de Sevilla, Health & Territory Research (HTR), Sevilla, Spain, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹University of Seville, Sevilla, Spain
Background/Purpose: Previous studies have suggested there could be regional differences in clinical phenotype of axial spondyloarthritis (axSpA). This analysis aims to explore differences in axSpA…
Abstract Number: 2355 • ACR Convergence 2023
Proteome-based Stratification of Therapeutic Target Population for MT-6194 in Systemic Sclerosis with Pulmonary Arterial Hypertension
Yuuichi Ono¹, Akira Mogami¹, Ryuta Saito², Noriyasu Seki¹, Sho Ishigaki³, Hiroshi Takei³, Keiko Yoshimoto³, Kenji Chiba¹, Tsutomu Takeuchi⁴ and Yuko Kaneko⁵, ¹Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ²Mitsubishi Tanabe Pharma Corporaion, Yokohama, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: SSc-related pulmonary arterial hypertension (SSc-PAH) is the one of the leading causes of death in SSc. Early diagnosis and effective therapy for SSc-PAH may…
Abstract Number: 2503 • ACR Convergence 2023
Cytokines Regulate the Fibrotic Response of Growth Factors in Joint Fibroblast-like Synoviocytes
Sofie Falkenløve Madsen¹, Mikkel Rathsach Andersen², Alexander Scheller Madrid², Signe Holm Nielsen³, Morten Karsdal³, Christian Thudium³ and Anne-Christine Bay-Jensen³, ¹University of Copenhagen, Herlev, Denmark, ²Herlev-Gentofte Hospital, Gentofte, Denmark, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) and osteoarthritis (OA) are characterized by inflammation, joint swelling, stiffness, and pain. A fibroid phenotype has been identified in RA, where…
Abstract Number: 0024 • ACR Convergence 2023
Detection of Synovial Signatures in Peripheral Blood of Patients with Rheumatoid Arthritis via a Novel Blood-Based DNA Capture Assay
Peter C. Taylor¹, Jenya Antonova², Jennifer Geis³, Katharine Dilger³, David Chernoff⁴, Diana Abdueva³, Nancy Shadick⁵ and Michael Weinblatt⁶, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Compass Strategy and Research, Inc., San Francisco, CA, ³Aqtual Inc., Hayward, CA, ⁴Chernoff Consulting, Sausalito, CA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Harvard Medical School, Waban, MA
Background/Purpose: In rheumatoid arthritis [RA], synovial biopsies were shown to guide therapy selection1. However, biopsies require special training for clinicians and are semi-invasive for patients.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].